Background/Aims: Prolactin (PRL) is produced by the anterior pituitary gland. It exerts its role on the breast gland but also plays a modulatory role in autoimmune mechanisms. Celiac disease (CD) is a gluten-sensitive autoimmune enteropathy sometimes associated with autoimmune endocrinopathies. No data on PRL levels in CD patients are available at diagnosis, and no conclusive data are reported. Methods: We aimed to evaluate PRL secretion in newly diagnosed CD pediatric patients and, in the case of hyperprolactinemia, any changes in its levels while the patients were on a gluten-free diet (GFD). We recruited 67 patients and 39 healthy controls. Results: PRL was statistically higher in the CD patients (13.5 ± 9.2 ng/ml) than in the controls (8.5 ± 5.0 ng/ml). In the CD group, PRL was inversely correlated with the age at diagnosis (r = -0.326; p = 0.007). In patients with hyperprolactinemia at diagnosis, PRL decreased after 6 months of GFD. Conclusion: This paper confirms that PRL may be increased at diagnosis of CD and shows, for the first time, that it decreases after a short course of GFD. Changes in the levels of inflammatory cytokines in CD may account for changes in PRL levels. Younger patients seem more prone to develop hyperprolactinemia than older ones.

Gujral N, Freeman HJ, Thomson AB: Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol 2012;18:6036-6059.
Rewers M: Epidemiology of celiac disease: what are the prevalence, incidence and progression of celiac disease? Gastroenterology 2005;128(4 suppl 1):S47-S51.
Sollid LM: Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002;2:647-655.
Kagnoff MF: Overview and pathogenesis of celiac disease. Gastroenterology 2005;128:10-18.
Di Sabatino A, Corazza GR: Coeliac disease. Lancet 2009;373:1480-1493.
Cianci R, Cammarota G, Frisullo G: Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal immunological niche in coeliac disease after gluten-free diet. Clin Transl Gastroenterol 2012;3:e28.
Dieterich W, Ehnis T, Bauer M: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
Collin P, Kaukinen K, Välimäki M: Endocrinological disorders and celiac disease. Endocr Rev 2002;23:464-483.
Bodd M, Raki M, Tollefsen S, Fallang LE, Bergseng E, Lundin KE, Sollid LM: HLA-DQ2-restricted gluten-reactive T cells produce IL-21 but not IL-17 or IL-22. Mucosal Immunol 2010;3:594-601.
Collin P, Hakanen M, Salmi J, Maki M, Kaukinen K: Autoimmune hypopituitarism in patients with coeliac disease: symptoms confusingly similar. Scand J Gastroenterol 2001;36:558-560.
Giovenale D, Meazza C, Cardinale GM, Sposito M, Mastrangelo C, Messini B, Citro G, Delvecchio M, Di Maio S, Bozzola M: The prevalence of growth hormone deficiency and celiac disease in short children. Clin Med Res 2006;4:180-183.
Delvecchio M, De Bellis A, Francavilla R, Rutigliano V, Predieri B, Indrio F, De Venuto D, Sinisi AA, Bizzarro A, Bellastella A, Iughetti L, Cavallo L; Italian Autoimmune Hypophysitis Network Study: Anti-pituitary antibodies in children with newly diagnosed celiac disease: a novel finding contributing to linear-growth impairment. Am J Gastroenterol 2010;105:691-696.
Horseman ND: Basic physiology: prolactin; in De Groot LJ, Jameson JL (eds): Endocrinology, ed 4. Philadelphia, Saunders, 2001, pp 209-220.
De Bellis A, Bizzarro A, Pivoncello R: Prolactin and autoimmunity. Pituitary 2005;8:25-30.
Chikanza IC: Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann NY Acad Sci 1999;876:119-123.
Reifen R, Briskila D, Maislas M: Serum prolactin in celiac disease: a marker for disease activity. Arch Dis Child 1997;77:155-157.
Kapur G, Patwari AK, Narayan S: Serum prolactin in celiac disease. J Trop Pediatr 2004;50:37-40.
Varkonyi A, Boda M, Endreffy E: Coeliac disease: always something to discover. Scand J Gastroenterol Suppl 1998;228:122-129.
Gocyla U, Szczepanski Z, Kalita B: Serum prolactin concentration in children with celiac disease. Pediatr Pol 1996;71:797-800.
Fanciulli G, Tomasi PA, Delitalia G: Serum prolactin in celiac schoolchildren. Arch Dis Child 2003;88:945-946.
Theintz GE, Nusslè D, Cox J: Prolactin and the gut: a controversy. J Pediatr Gatroenterol Nutr 1984;3:523-528.
Cacciari E, Milani S, Balsamo A, Spada E, Bona G, Cavallo L, Cerutti F, Gargantini L, Greggio N, Tonini G, Cicognani A: Italian cross-sectional growth charts for height, weight and BMI (2 to 20 years). J Endocrinol Invest 2006;29:581-593.
Jara LJ, Vera-Lastra O, Miranda JM, Alcala M, Alvarez-Nemegyei J: Prolactin in human systemic lupus erythematosus. Lupus 2001;10:748-756.
Chikanza IC, Petrou P, Chrousos G, Kingsley G, Panayi GS: Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. Br J Rheumatol 1993;32:445-448.
El Miedany YM, Ahmed I, Moustafa H, El Baddini M: Hyperprolactinemia in Sjogren's syndrome: a patient subset or a disease manifestation? Joint Bone Spine 2004;71:203-208.
Neidhart M: Prolactin in autoimmune diseases. Proc Soc Exp Biol Med 1998;217:408-419.
Li J, Teng W, Shan Z: Effects of prolactin on HLA-DR and CD40 expressions by human thyrocytes. Chin Med J 2001;114:1151-1156.
Giusti M, Foppiani L, Fazzuoli L, Molinari E, Guido R, Valenti S, Giordano G: An increased prevalence of thyroid echographic and autoimmune changes in hyperprolactinemic women on therapy with dopaminergic drugs (in Italian). Recenti Prog Med 1999;90:147-151.
Lever EG, McKerron CG: Auto-immune Addison's disease associated with hyperprolactinaemia. Clin Endocrinol 1984;21:451-457.
Thodou E, Asa SL, Kontogeorgos G, Kovacs K, Horvath E, Ezzat S: Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995;80:2302-2311.
Azar ST, Yamout B: Prolactin secretion is increased in patients with multiple sclerosis. Endocr Res 1999;25:207-214.
Palová-Jelínková L, Dánová K, Drasarová H, Dvorák M, Funda DP, Fundová P, Kotrbová-Kozak A, Cerná M, Kamanová J, Martin SF, Freudenberg M, Tucková L: Pepsin digest of wheat gliadin fraction increases production of IL-1β via TLR4/MyD88/TRIF/MAPK/NF-kB signaling pathway and an NLRP3 inflammasome activation. PLoS One 2013;8:e62426.
Harris KM, Fasano A, Mann DL: Cutting edge: IL-1 controls the IL-23 response induced by gliadin, the etiologic agent in celiac disease. J Immunol 2008;181:4457-4460.
Kapoor A, Patwari AK, Kumar P, Jain A, Narayan S: Serum soluble interleukin-2 receptor, interleukin-6 and tumor necrosis factor alpha as markers of celiac disease activity. Indian J Pediatr 2013;80:108-113.
Bayardo M, Punzi F, Bondar C, Chopita N, Chirdo F: Transglutaminase 2 expression is enhanced synergistically by interferon-gamma and tumour necrosis factor-alpha in human small intestine. Clin Exp Immunol 2012;168:95-104.
Laparra Llopis JM, Sanz Herranz Y: Gliadins induce TNFalpha production through cAMP-dependent protein kinase A activation in intestinal cells (Caco-2). J Physiol Biochem 2010;66:153-159.
Manavalan JS, Hernandez L, Shah JG, Konikkara J, Naiyer AJ, Lee AR, Ciaccio E, Minaya MT, Green PH, Bhagat G: Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol 2010;71:50-57.
Street ME, Volta C, Ziveri MA, Zanacca C, Banchini G, Viani I, Rossi M, Virdis R, Bernasconi S: Changes and relationships of IGFS and IGFBPS and cytokines in coeliac disease at diagnosis and on gluten-free diet. Clin Endocrinol 2008;68:22-28.
Matera L, Mori M: Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon gamma by natural killer and T cells. Ann NY Acad Sci 2000;917:505-511.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.